Victoria M. McLeod

The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer

Stephin J. Vervoort, Sarah A. Welsh, Jennifer R. Devlin et al. · Cell · 2021 · 221 citations · Full text

Life Sciences, Cancer Biology, Molecular Biology +9

Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy

Lisa M. Kaminskas, Victoria M. McLeod, Gemma M. Ryan et al. · Journal of Controlled Release · 2014 · 188 citations

Pharmacy, Oncology, Pharmacology +17

A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems

Lisa M. Kaminskas, Victoria M. McLeod, Brian D. Kelly et al. · Nanomedicine Nanotechnology Biology and Medicine · 2011 · 171 citations

Pharmacy, Pharmacokinetics, Pharmacology +16

PEGylation of polylysine dendrimers improves absorption and lymphatic targeting following SC administration in rats

Lisa M. Kaminskas, Jagannath Kota, Victoria M. McLeod et al. · Journal of Controlled Release · 2009 · 144 citations

Pharmacy, Pharmaceutics, Pharmacology +12

Pharmacokinetics and Tumor Disposition of PEGylated, Methotrexate Conjugated Poly-<scp>l</scp>-lysine Dendrimers

Lisa M. Kaminskas, Brian D. Kelly, Victoria M. McLeod et al. · Molecular Pharmaceutics · 2009 · 139 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +14